Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported option exercises and a share sale. On June 9, 2026, she exercised stock options for 20,000 shares of Class A Common Stock at exercise prices of $18.93, $6.89, and $1.08 per share.
On the same date, she sold 20,000 shares in an open-market transaction at an average price of $122.81 per share pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, she directly held 58,117 shares of Class A Common Stock.
GSK plc, together with GlaxoSmithKline LLC and acquisition subsidiaries, announced a planned cash tender offer to acquire all issued and outstanding Class A and Class B shares of Nuvalent, Inc. The parties referenced an Agreement and Plan of Merger dated June 9, 2026. The announcement is a pre-commencement communication and the tender offer has not yet commenced. The filing states that when the offer is launched GSK plc, Parent and Purchaser will file a Tender Offer Statement on Schedule TO and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9. The documents will be made available free on the SEC website and on the companies' investor sites. The communication contains forward-looking statements and directs readers to the "Risk Factors" in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2025.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving Class A Common Stock. On June 8, 2026, he sold a total of 30,000 shares in open-market sales at weighted average prices in the high-$80 range, pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. On the same date, he exercised stock options for 30,000 shares at an exercise price of $18.93 per share. Following these transactions, he directly holds 354,879 shares of Nuvalent Class A Common Stock and 148,686 stock options with a stated exercise price of $18.93 per share and expiration in 2032.
GSK plc announced a planned cash tender offer to acquire all issued and outstanding Class A and Class B common shares of Nuvalent, Inc. The parties entered into an Agreement and Plan of Merger dated June 9, 2026. The tender offer has not commenced; when it does, the offerors will file a Tender Offer Statement on Schedule TO and the company will file a Solicitation/Recommendation Statement on Schedule 14D-9. Tender offer materials will be made available to Nuvalent stockholders and posted on the SEC website and the parties' investor websites.
NUVL submitted a Rule 144 notice to sell 48,500 shares of Class A Common stock tied to a stock option exercise on 06/09/2026. The filing lists cash as the payment method. It also discloses three prior small sales of 5,500 shares each by Darlene Noci on 03/30/2026, 04/29/2026, and 05/28/2026.
GSK plc has announced a planned cash tender offer to acquire all issued and outstanding Class A and Class B common stock of Nuvalent, Inc. The announcement references an Agreement and Plan of Merger dated June 9, 2026 between GlaxoSmithKline LLC, Harmony Row Acquisition Co. and Nuvalent.
The communication is a pre-commencement Schedule TO filing and states the tender offer has not yet commenced. When the offer is launched, GSK plc, Parent and Purchaser will file a Tender Offer Statement on Schedule TO and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9.
Nuvalent, Inc. entered into a Merger Agreement for GSK to acquire all Class A and Class B shares via a tender offer at $124.00 per share in cash. Following the offer, GSK’s subsidiary will merge into Nuvalent under Delaware law, with remaining shares also cashed out at the same price.
The offer requires at least a majority of Nuvalent’s Class A shares to be tendered and customary regulatory clearances, including expiration of the Hart-Scott-Rodino waiting period. An outside date of December 9, 2026 applies. Certain shareholders owning about 28% of Class A shares agreed to tender. Nuvalent must pay a $350,475,000 termination fee in specified scenarios, including accepting a superior proposal or a board recommendation change.
GSK values the equity of Nuvalent at about $10.6 billion and expects the deal, funded mainly with debt and cash, to contribute to its revenue growth from 2027. GSK states the $124 price reflects a 40% premium to the last closing price and a 26% premium to the 30-day VWAP.
NUVL registers 90,000 Class A Common shares related to a stock option exercise effective 06/08/2026.
The filing lists the method as cash and identifies the transaction type as a stock option exercise with shares to be sold through J.P. Morgan Securities LLC. The excerpt also reports two prior dispositions by James Richard Porter of 30,000 shares each on 04/06/2026 and 05/04/2026, with post-sale positions shown as 3,113,217 and 3,050,772, respectively.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported a mix of stock sales and an option exercise in Class A Common Stock. On June 1, 2026, she sold a total of 11,430 shares in multiple open-market transactions at weighted average prices within ranges from $94.48 to $104.19 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025.
On the same date, she exercised stock options to acquire 11,430 shares at an exercise price of $6.89 per share. Following these transactions, Balcom directly owned 96,963 shares of Nuvalent Class A Common Stock, indicating she retained a substantial equity position after the activity.
Nuvalent, Inc.’s Chief Development Officer, Darlene Noci, reported a combination of option exercise and share sales in Class A Common Stock. On May 28, 2026, she exercised stock options to acquire 5,500 shares at an exercise price of $27.85 per share and sold 5,500 shares in open-market transactions.
The sales occurred in multiple trades at reported weighted average prices including $109.76, $109.30, $108.01, $107.33, and $106.26 per share. According to a footnote, these transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2024, indicating they were pre-arranged rather than timed discretionarily.